Axovant Sciences (NASDAQ:AXON)‘s stock had its “hold” rating reiterated by stock analysts at Cowen in a research report issued to clients and investors on Tuesday.
The analysts wrote, “We maintain our BUY rating and $25 PT for SVRA shares.””
Other analysts have also issued research reports about the company. ValuEngine upgraded Axovant Sciences from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Zacks Investment Research upgraded Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a research note on Wednesday, January 31st. Oppenheimer reiterated a “hold” rating on shares of Axovant Sciences in a research note on Tuesday. Piper Jaffray Companies reiterated a “hold” rating on shares of Axovant Sciences in a research note on Friday, November 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of Axovant Sciences in a research note on Friday, December 1st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have assigned a buy rating to the company’s stock. Axovant Sciences currently has an average rating of “Hold” and an average target price of $13.61.
Shares of Axovant Sciences (AXON) opened at $1.63 on Tuesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 5.94 and a quick ratio of 5.94. Axovant Sciences has a 52 week low of $1.47 and a 52 week high of $27.98. The firm has a market capitalization of $175.57 and a price-to-earnings ratio of -0.69.
Several institutional investors have recently made changes to their positions in AXON. BlackRock Inc. increased its stake in shares of Axovant Sciences by 99.8% during the fourth quarter. BlackRock Inc. now owns 2,912,219 shares of the biotechnology company’s stock valued at $15,347,000 after buying an additional 1,454,454 shares during the period. OxFORD Asset Management LLP increased its stake in shares of Axovant Sciences by 842.1% during the third quarter. OxFORD Asset Management LLP now owns 869,834 shares of the biotechnology company’s stock valued at $5,838,000 after buying an additional 777,505 shares during the period. Millennium Management LLC increased its stake in shares of Axovant Sciences by 445.0% during the fourth quarter. Millennium Management LLC now owns 482,964 shares of the biotechnology company’s stock valued at $2,545,000 after buying an additional 622,964 shares during the period. Eagle Asset Management Inc. purchased a new position in shares of Axovant Sciences during the third quarter valued at $4,471,000. Finally, Hudson Bay Capital Management LP purchased a new position in shares of Axovant Sciences during the fourth quarter valued at $1,845,000. Hedge funds and other institutional investors own 96.82% of the company’s stock.
WARNING: This story was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States and international trademark & copyright law. The correct version of this story can be viewed at https://www.dispatchtribunal.com/2018/02/15/axovant-sciences-axon-rating-reiterated-by-cowen.html.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.